Aquestive Therapeutics (AQST) vs Capricor Therapeutics (CAPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Capricor Therapeutics (CAPR) has outperformed Aquestive Therapeutics (AQST) over the past year, gaining 32.0% versus a loss of 39.5%. Over five years, CAPR leads with a +122.6% price change compared with -45.7% for AQST. Capricor Therapeutics is the larger company by market cap ($441.3 million vs $434.9 million), about 1.0 times the size, while Aquestive Therapeutics is growing revenue faster (-22.6% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | CAPR |
|---|---|---|
| Share price | $3.46 | $7.59 |
| Market cap | $434.88M | $441.30M |
| 1-day change | -6.61% | +0.80% |
| YTD return | -46.44% | -73.70% |
| 1-year return | -39.51% | +32.00% |
| 5-year return | -45.68% | +122.58% |
| EPS (TTM) | $-0.65 | $-2.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.55M | $0 |
| Revenue growth (YoY) | -22.61% | -100.00% |
| Net income (latest FY) | $-83.78M | $-105.04M |
| Gross margin | 58.35% | — |
| Operating margin | -159.50% | — |
| Net margin | -188.09% | — |
| 52-week high | $6.74 | $40.37 |
| 52-week low | $2.93 | $2.96 |
| Distance from 52-week high | -48.63% | -81.20% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +169.65% | +259.03% |
| Average volume | 2.41M | 4.73M |
| Shares outstanding | 125.69M | 58.14M |
| Employees | 147 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAPR has outperformed AQST by 71.5 percentage points over the past year.
- Aquestive Therapeutics grew revenue faster in its latest fiscal year (-22.61% vs -100.00%).
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
AQST vs CAPR FAQ
Which is bigger, Aquestive Therapeutics or Capricor Therapeutics?
Capricor Therapeutics (CAPR) is larger, with a market capitalization of $441.30M compared with $434.88M for Aquestive Therapeutics (AQST).
Which stock has performed better over the past year, AQST or CAPR?
CAPR returned +32.00% over the past 12 months, compared with -39.51% for AQST (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Capricor Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.